Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small
cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin
and paclitaxel for two cycles or until disease progression or until the patient exhibits
intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the
duration of the study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company ImClone LLC
Collaborators:
Greenwich Hospital Indiana University IUPUI, Indianapolis, IN University of Colorado, Denver